Chebli, J.M.F.;                     Parra, R.S.;                     Flores, C.;                     Moraes, A.C.;                     Nones, R.B.;                     Gomes, T.N.F.;                     Perdomo, A.M.B.;                     Scapini, G.;                     Zaltman, C.    
        Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn’s Disease: Results from an Early Access Program in Brazil. J. Clin. Med. 2022, 11, 6481.
    https://doi.org/10.3390/jcm11216481
    AMA Style
    
                                Chebli JMF,                                 Parra RS,                                 Flores C,                                 Moraes AC,                                 Nones RB,                                 Gomes TNF,                                 Perdomo AMB,                                 Scapini G,                                 Zaltman C.        
                Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn’s Disease: Results from an Early Access Program in Brazil. Journal of Clinical Medicine. 2022; 11(21):6481.
        https://doi.org/10.3390/jcm11216481
    
    Chicago/Turabian Style
    
                                Chebli, Julio Maria Fonseca,                                 Rogério Serafim Parra,                                 Cristina Flores,                                 Antonio Carlos Moraes,                                 Rodrigo Bremer Nones,                                 Tarcia Nogueira Ferreira Gomes,                                 Ana Maria Bravo Perdomo,                                 Gustavo Scapini,                                 and Cyrla Zaltman.        
                2022. "Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn’s Disease: Results from an Early Access Program in Brazil" Journal of Clinical Medicine 11, no. 21: 6481.
        https://doi.org/10.3390/jcm11216481
    
    APA Style
    
                                Chebli, J. M. F.,                                 Parra, R. S.,                                 Flores, C.,                                 Moraes, A. C.,                                 Nones, R. B.,                                 Gomes, T. N. F.,                                 Perdomo, A. M. B.,                                 Scapini, G.,                                 & Zaltman, C.        
        
        (2022). Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn’s Disease: Results from an Early Access Program in Brazil. Journal of Clinical Medicine, 11(21), 6481.
        https://doi.org/10.3390/jcm11216481